학술논문
71P - Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
Document Type
Abstract
Author
Source
In Annals of Oncology December 2018 29 Supplement 10:x25-x25
Subject
Language
ISSN
0923-7534